Nanoparticle-Encased Drug Shows Promise as Triple-Negative Breast Cancer Therapy
News Oct 02, 2018 | Original story from George Washington University (GW)
Heterogeneity in Triple-Negative Breast Cancer. Credit: National Cancer Institute
Approximately 10-20 percent of diagnosed breast cancers are found to be triple-negative, meaning the breast cancer cells test negative for estrogen and progesterone receptors as well as HER2 receptors, genes that can play a role in the development of breast cancer. Triple-negative breast cancer can be more aggressive and difficult to treat as the cancer cells do not respond to hormonal therapies or therapies that target HER2 receptors.
A new study from the George Washington University (GW) Cancer Center found that nanoparticle-encapsulated doxorubicin is promising in the treatment of triple-negative breast cancer. Doxorubicin is a well-known anthracycline drug class used primarily in combination chemotherapy.
The majority of patients with triple-negative breast cancer receive doses of doxorubicin along with taxane and cyclophosphamide as preoperative chemotherapy. About 25-45 percent of those patients respond to this medication and have excellent long-term prognosis.
"Nanomedicine is a very exciting avenue in modern drug development," said Adam Friedman, MD, director of the Supportive Oncodermatology Clinic at GW Cancer Center, professor of dermatology at the GW School of Medicine and Health Sciences, and senior author of the study. "Nanotechnology offers many benefits, including the ability to purposefully customize your drug or diagnostic at the atomic scale, enhancing its ability to interact with its biological target and improve outcomes and potentially safety."
In order to determine the most effective delivery of doxorubicin when encapsulated in a nanoparticle platform, Friedman and his collaborators at the Albert Einstein College of Medicine, synthesized several formulations of doxorubicin containing nanoparticles to identify nanoparticle characteristics which best impact biologic activity against several resistant cancer cell lines.
With the nanoparticle, the team manipulated the size and timed release of the medication and found that increased cell kill in triple-negative breast cancer cells was associated with the smallest size of nanoparticles and the slowest release of doxorubicin.
"This study provides clues for new potential strategies utilizing and manipulating nanotechnology to overcome cancer cell drug resistance," said Friedman. "We have our work cut out for us, but this study shows that we are moving in the right direction."
This article has been republished from materials provided by George Washington University (GW). Note: material may have been edited for length and content. For further information, please contact the cited source.
A team of researchers has discovered a combination of pharmaceutical drugs that not only increases healthy lifespan in the microscopic worm Caenorhabditis elegans (C. elegans), but also delays the rate of ageing in them, a finding that could someday mean longer, healthier lives for humans.READ MORE
14th World Congress on Medicinal Chemistry and Drug Design
Jun 10 - Jun 11, 2019
International Conference on e-Health and Healthcare Innovations
May 08 - May 09, 2019
12th International Conference on Cancer Stem Cells and Oncology Research
Jul 18 - Jul 19, 2019
4th Annual Congress on Nanomedicine and Drug Delivery
Apr 04 - Apr 06, 2019